Core Viewpoint - NKGen Biotech, Inc. is set to present Phase 1 clinical data for its NK cell therapy, troculeucel, targeting moderate Alzheimer's disease at the ASGCT Annual Meeting in May 2025 [1][2] Group 1: Presentation Details - The presentation titled "Use of Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Patients with Alzheimer's Disease" will be delivered by Dr. Paul Y. Song [2] - The session is scheduled for May 14, 2025, from 2:30 to 2:45 PM Central Time at NOLA Theater B [2] - Previous data on troculeucel's efficacy in Alzheimer's and solid tumors is available on the company's website [2] Group 2: About Troculeucel - Troculeucel is an innovative, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate [3] - It is being developed for neurodegenerative disorders and various cancers, with the International Nonproprietary Name (INN) for troculeucel being SNK01, approved by the WHO [3] Group 3: About NKGen Biotech - NKGen is a clinical-stage biotechnology company focused on developing and commercializing autologous and allogeneic NK cell therapeutics [4] - The company is headquartered in Santa Ana, California [4]

Core Insights - Vigil Neuroscience is advancing its clinical programs, with key milestones expected in 2025, including the final analysis of iluzanebart in ALSP and the initiation of a Phase 2 trial for VG-3927 in Alzheimer's disease [1][2][3] Clinical Development Updates - The final analysis from the IGNITE Phase 2 clinical trial for iluzanebart is scheduled for Q2 2025, with plans for an accelerated approval pathway in ALSP [3] - VG-3927 has shown positive Phase 1 data, supporting the initiation of a Phase 2 trial in Q3 2025 for Alzheimer's disease [2][4] - The Phase 1 trial for VG-3927 included 115 participants, demonstrating a favorable safety profile and significant pharmacokinetic and pharmacodynamic results [4] Financial Performance - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities of $87.1 million, down from $97.8 million at the end of 2024, with expectations to fund operations into 2026 [9][13] - Research and Development (R&D) expenses for Q1 2025 were $16.5 million, an increase from $14.3 million in Q1 2024, driven by higher costs in preclinical and manufacturing activities [9][11] - The net loss for Q1 2025 was $22.4 million, compared to $19.9 million for the same period in 2024, with a net loss per share of $0.49 [9][11]

Core Viewpoint - Skye Bioscience, Inc. is set to discuss its Q1 2025 financial results in a conference call on May 8, 2025, highlighting its focus on therapeutic pathways for obesity and metabolic health disorders [1][2]. Company Overview - Skye Bioscience is a clinical-stage biotechnology company dedicated to developing next-generation molecules that target G-protein coupled receptors for metabolic health [3]. - The company is conducting a Phase 2 clinical trial for nimacimab, an antibody that inhibits CB1, and is also evaluating its combination with a GLP-1R agonist (Wegovy®) [3]. Upcoming Events - A conference call will take place on May 8, 2025, at 1:30 p.m. PT/4:30 p.m. ET to discuss the company's financial results, with an earnings press release to be issued after market close on the same day [1][2].

Core Insights - Ginkgo Bioworks has made significant progress in its restructuring efforts, targeting $250 million in cost savings by Q3 2025 [1][3][7] - The company reported a total revenue of $48 million for Q1 2025, a 27% increase from $38 million in the same period last year, primarily due to a $7 million non-cash revenue release [6][22] - Ginkgo's Solutions business is becoming a trusted R&D service provider for the US Government and biopharma industry, while its Tools business is gaining traction in AI-related opportunities [3][7] Financial Performance - Q1 2025 total revenue was $48 million, with $31 million from Cell Engineering (up 10% year-over-year) and $10 million from Biosecurity (flat year-over-year) [6][22] - The company reported a GAAP net loss of $91 million for Q1 2025, an improvement from a net loss of $166 million in the prior year [6][22] - Adjusted EBITDA for Q1 2025 was $(47) million, an improvement from $(117) million in the prior year, driven by increased revenue and reduced operating expenses [6][22] Strategic Positioning - Ginkgo is well-positioned in the biotechnology sector, with 28 US Government projects and a contracted backlog of approximately $180 million [7] - The company is focusing on biosecurity and R&D services, which are deemed critical by national policy reports [7] - Ginkgo's Datapoints and Automation offerings are generating new deals, including a recent agreement with Aura Genetics [7] Guidance and Outlook - Ginkgo has updated its 2025 guidance to reflect total revenue expectations of $160-$180 million, with Cell Engineering revenue projected at $110-$130 million and Biosecurity revenue at least $50 million [5][13] - The company aims to achieve Adjusted EBITDA breakeven by the end of 2026 [7]

Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care;All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 do ...

Core Viewpoint - Cellectis, a clinical-stage biotechnology company, is set to report its financial results for Q1 2025 on May 12, 2025, after the US market closes [1]. Company Overview - Cellectis specializes in developing life-saving cell and gene therapies using its innovative gene-editing platform [2][3]. - The company employs an allogeneic approach for CAR T immunotherapies in oncology, focusing on off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [2]. - Cellectis is one of the few end-to-end gene editing companies, controlling the entire cell and gene therapy value chain from start to finish through its in-house manufacturing capabilities [2]. Locations and Listings - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [3]. - The company is publicly traded on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS [3].

Core Insights - BioAtla, Inc. reported its financial results for Q1 2025, highlighting advancements in its Conditionally Active Biologic (CAB) platform and ongoing clinical trials for cancer therapies [1][8]. Financial Performance - Research and development (R&D) expenses for Q1 2025 were $12.4 million, down from $18.9 million in Q1 2024, primarily due to reduced clinical development costs [8]. - General and administrative (G&A) expenses decreased to $5.3 million in Q1 2025 from $5.6 million in Q1 2024 [9]. - The net loss for Q1 2025 was $15.3 million, compared to a net loss of $23.2 million in the same quarter of 2024 [9]. - Cash and cash equivalents as of March 31, 2025, were $32.4 million, down from $49.0 million at the end of 2024, with expectations to fund operations through key clinical readouts in 1H 2026 [11]. Clinical Developments - The Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is ongoing, with the first three patients dosed at 300 micrograms, and data readout expected in mid-2025 [5][6]. - Mecbotamab vedotin (Mec-V) demonstrated a 2-year landmark survival rate of 59% in mKRAS non-small cell lung cancer (NSCLC) patients, significantly higher than the less than 20% survival rate reported for standard care [5][6]. - Ozuriftamab vedotin (Oz-V) continues to show promising results in HPV-positive squamous cell carcinoma of the head and neck, with a disease control rate of 100% and an overall response rate of 45% [6][5]. Strategic Initiatives - The company is utilizing Fast Track Designation from the FDA for discussions regarding a proposed Phase 3 study for Oz-V in treatment-refractory metastatic HPV-positive SCCHN [13]. - BioAtla is focusing on its two internal priority programs and expects cost reductions from its recent restructuring [11]. Upcoming Events - Management will host a conference call and webcast on May 6, 2025, to discuss the financial results and clinical updates [12]. - BioAtla has presentations scheduled at major oncology conferences, including the ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress [13].

Shares of Recursion Pharmaceuticals (RXRX -11.57%) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P 500 and Nasdaq Composite both slipped by 0.6%.The data from an April survey revealed Tuesday showed that the biotech industry is fearful that President Donald Trump's federal research cuts will make raising capital more challenging. This comes just a day after Recursion revealed its disappointing first-quarter earni ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ETSAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Qu ...